These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12542480)

  • 21. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
    Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
    Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M; Uemura T; Minaguchi H
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.
    Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J
    Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
    Fonseca R; Trendle MC; Leong T; Kyle RA; Oken MM; Kay NE; Van Ness B; Greipp PR
    Br J Haematol; 2000 Apr; 109(1):24-9. PubMed ID: 10848778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
    St Clair EW; Moak SA; Wilkinson WE; Sanders L; Lang T; Greenwald RA
    J Rheumatol; 1998 Aug; 25(8):1472-9. PubMed ID: 9712086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.
    Gram J; Junker P; Nielsen HK; Bollerslev J
    Bone; 1998 Sep; 23(3):297-302. PubMed ID: 9737353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links.
    Välimäki MJ; Tähtelä R; Jones JD; Peterson JM; Riggs BL
    Eur J Endocrinol; 1994 Sep; 131(3):258-62. PubMed ID: 7921210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in urinary excretions of C-telopeptide and cross-linked N-telopeptide of type I collagen during pregnancy and puerperium.
    Yamaga A; Taga M; Minaguchi H
    Endocr J; 1997 Oct; 44(5):733-8. PubMed ID: 9466331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.
    Gorai I; Taguchi Y; Chaki O; Kikuchi R; Nakayama M; Yang BC; Yokota S; Minaguchi H
    J Clin Endocrinol Metab; 1998 Feb; 83(2):326-32. PubMed ID: 9467535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
    de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
    Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
    Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
    Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
    Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
    Franke S; Lehmann G; Abendroth K; Hein G; Stein G
    Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type I collagen and procollagen fragments in patients with metabolic bone diseases.
    Lin JS; Kao JT; Tsai KS
    J Formos Med Assoc; 1996 Jul; 95(7):523-9. PubMed ID: 8840753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis.
    Lund T; Abildgaard N; Andersen TL; Delaisse JM; Plesner T
    Eur J Haematol; 2010 May; 84(5):412-20. PubMed ID: 20070853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.